StocksMedium•18 November 2026•
1 min read
Bristol Myers Squibb Reports Positive KarXT Trial Data for Alzheimer's Psychosis
Key Facts
1Preliminary Phase 3 data showed that KarXT treatment reduced hallucinations and delusions in Alzheimer's patients.
Bristol Myers Squibb released preliminary Phase 3 trial data showing that its drug KarXT effectively reduces psychosis symptoms in Alzheimer's patients. Benzinga reported that the treatment demonstrated a reduction in hallucinations and delusions during the clinical testing phase.
The company is testing the efficacy of KarXT specifically for treating hallucinations and delusions in both short- and long-term scenarios. These positive preliminary results from the Phase 3 pipeline candidate represent a significant development for Bristol Myers Squibb as it evaluates the drug's impact on Alzheimer's-related psychosis.